Clinical progress of calcitonin and rheumatic diseases
10.13431/j.cnki.immunol.j.20250018
- VernacularTitle:钙卫蛋白与风湿性疾病相关的临床进展
- Author:
Li ZHANG
1
;
Xiaodong LUO
1
Author Information
1. 400000,重庆市未成年犯管教所医院内科
- Publication Type:Journal Article
- Keywords:
Calprotectin;
Rheumatic diseases;
Clinical progresses
- From:
Immunological Journal
2025;41(2):123-128
- CountryChina
- Language:Chinese
-
Abstract:
Calprotectin,called MRP8/14 or S100A8/A9,is a heterodimer formed by two proteins,S100A8 and S100A9.It is mainly produced by activated monocytes and neutrophils in circulation and in inflamed tissues,thereby promoting the inflammatory response in vivo and in vitro as an important innate immune proinflammatory factor.Calprotectin is elevated in many inflammatory conditions and can be detected in blood,urine,faeces,cerebrospinal fluid,salivary synovial fluid and colon biopsy tissue.Due to its immunological features,calprotectin plays an important role in tumor,autoimmune disease,infection and other diseases.In recent years,more and more studies have been conducted on the relationship between calprotectin and rheumatic diseases,and the mechanism has also been gradually deepened.Many clinical trials have shown that calprotectin is correlated with rheumatic diseases in terms of reflecting disease activity or predicting prognosis.In this review,we will systematically summarize the relationship between calprotectin and some rheumatic diseases and its clinical progresses.
